Le Lézard
Classified in: Health, Science and technology, Business
Subject: CON

BC Platforms Partners with Leading European Genomics Service Provider Center Life & Brain to Expand Genotyping Services Across Europe


ZURICH and BOSTON, Dec. 6, 2019 /PRNewswire/ -- BC Platforms, a world leader in genomic data management and analytics, today announced that it has formed a partnership with Life & Brain Genomics, a division of Life & Brain GmbH. Life & Brain Genomics is one of the leading European service providers for array-based omics analyses, supporting its customers from academia, industry and the healthcare sector with innovative products and scientific expertise from project planning to data analysis. The partnership will leverage BC Platforms' high performing solutions to securely integrate and analyse genetic array data to support Life & Brain's Genomics customer offerings.

BC Platforms will use a combination of its solutions, including BC|GENOME, BC|PIPE and BC|SAMPLE, to streamline Life & Brain's genetic array data input whilst ensuring quality control and sample management. This system will accelerate data delivery through process automation and interoperability. All of BC Platforms' modules are interoperable, designed to be integrated with other IT systems and instruments such as Illumina iScan, allowing our customers to spend more time on analysis and thereby increase turnaround.

Prof Markus Nöthen, CEO of Life & Brain, commented; "We are delighted to be working with BC Platforms, a leader in genomic data management and analytics, who in our opinion have the best bioinformatics pipeline for automated genotyping workflows. This partnership helps us to meet increased demand from our European customers that require our services for data production with high quality and timely delivery. BC Platforms' solution allows us to spend more time on revenue generating tasks to the benefit of our customers and their patients."

Nino da Silva, EVP EMEA-APAC, commented; "We are pleased to be selected to support Life & Brain Genomics by providing automated and streamlined processes for the production of their data. Life & Brain is one of the leading service providers in the whole of Europe and we look forward to supporting them with their genotyping services and also in supporting them to expand into new services in this field."

About BC Platforms

BC Platforms is a world leader in providing powerful genomic data management and analysis solutions. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. The company has launched and opened a global network of biobanks, known as BCRQUEST.COM, to provide genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms' vision is to build the world's leading analytics platform for healthcare and industry by 2020, providing access to diverse genomic and clinical data and samples from more than 5 million subjects consolidated from a global network of biobanks.

Founded in 1997 from an MIT Whitehead project spinoff, the Company has a strong scientific heritage underpinned by over 20 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. BC Platforms has global operations with its headquarters in Zurich, Switzerland, research and development in Espoo, Finland, and sales and marketing in London, Boston, Vancouver, and Singapore. For more information, please visit www.bcplatforms.com or follow us on Twitter @BCPlatforms.

About Life & Brain GmbH

Closing the gap between university research and business ? this is the rationale behind the biomedical and neuroscientific technology platform LIFE & BRAIN. In academia, translational developments frequently get stuck at an early stage because insufficient know-how and lack of financial resources prevent the development of a proof of concept required for further downstream commercialization and market entry.

As a Bonn-based company specializing in translational university medicine, LIFE & BRAIN acts as a 'revolving door' between academic research and industry. Innovative research findings are recognized early and developed further into marketable biomedical products and services.

Our expertise in the fields of genome research, stem cell technology, transgenic modelling and neurocognition creates the perfect environment for designing future-oriented services and products for disease-related research and the development of novel therapies.

LIFE & BRAIN Genomics is a leading European genomics service provider. We are specialized on Illumina (SNP genotyping and methylation analysis) array technology as well as PacBio single-molecule long-read sequencing. LIFE & BRAIN offers the complete workflow from Logistics and nucleic acid extraction down to bioinformatic analysis from a single source. With a strong scientific background in research on genetically complex disorders and an intense link to the Institute of Human Genetics, Life & Brain also offers complete project management for genomic projects.

Contact information:

BC Platforms:
Tero Silvola
BC Platforms AG  
tero.silvola@bcplatforms.com

Katja Stout
Scius Communications
katja@sciuscommunications.com

SOURCE BC Platforms


These press releases may also interest you

at 07:47
The Bureau of Science and Technology of Shunde district in China's Guangdong province has globally released today the list of 20 core technologies for pillar industries that need to be tackled, to pool resources for the continuous technological...

at 07:44
58.com Inc. ("58.com" or the "Company"), China's largest online market place for classifieds, today announced it has called an extraordinary general meeting of shareholders (the "EGM"), to be held on September 7, 2020 at 10:30 a.m. (Beijing time),...

at 07:35
PAR Technology Corporation ("PAR Technology" or the "Company") today announced its financial results for its second quarter ended June 30, 2020. Summary of Fiscal 2020 Second Quarter Revenues were reported at $45.7 million for the second...

at 07:35
Biogen and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for aducanumab, an...

at 07:30
According to the new research report, the "European Smart Home Market with COVID-19 Impact Analysis by Product (Lighting Control, Security & Access Control, HVAC Control, Home Healthcare), Software & Services (Proactive, Behavioural), and Region -...

at 07:30
(Note: During 2019, we acquired eight television stations being divested in the Nexstar/Tribune merger on Sept. 19 and 15 television stations from Cordillera on May 1. Results for the Local Media division are presented below both as reported and on...



News published on 6 december 2019 at 02:00 and distributed by: